1,976 results on '"Hillege, Hans"'
Search Results
2. Health Professionals' Expectations Versus Experiences of Internet-Based Telemonitoring: Survey Among Heart Failure Clinics
3. What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study
4. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction
5. Predictors and outcomes of heart failure with mid‐range ejection fraction
6. Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease
7. Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial
8. The Genetic Epidemiology of Pediatric Pulmonary Arterial Hypertension
9. Serial Measurements of N-Terminal Pro-B-Type Natriuretic Peptide Serum Level for Monitoring Pulmonary Arterial Hypertension in Children
10. Distinct Pathological Pathways in Patients With Heart Failure and Diabetes
11. 52 Genetic Loci Influencing Myocardial Mass
12. A combined clinical and biomarker approach to predict diuretic response in acute heart failure
13. Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration
14. A heart failure phenotype stratified model for predicting 1-year mortality in patients admitted with acute heart failure: results from an individual participant data meta-analysis of four prospective European cohorts
15. Sex differences in patients with repaired tetralogy of Fallot support a tailored approach for males and females: a cardiac magnetic resonance study
16. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction
17. Patient Preferences in the Medical Product Lifecycle
18. Conditional Financing of Drugs in the Netherlands: Past, Present, and Future—Results From Stakeholder Interviews
19. Gene-Age Interactions in Blood Pressure Regulation: A Large-Scale Investigation with the CHARGE, Global BPgen, and ICBP Consortia
20. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction
21. Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction
22. The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF
23. Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure
24. Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF
25. Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation
26. The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients
27. Trajectories of renal biomarkers and new‐onset heart failure in the general population: Findings from the PREVEND study
28. A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers
29. Fontan Circulation over Time
30. What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews
31. Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction
32. Serially measured circulating miR-22-3p is a biomarker for adverse clinical outcome in patients with chronic heart failure: The Bio-SHiFT study
33. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies
34. Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials)
35. Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure — Post-hoc analysis of the PROTECT trial
36. Determinants of temporal changes in galectin-3 level in the general population: Data of PREVEND
37. Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
38. Cardiac Magnetic Resonance Derived Left Ventricular Eccentricity Index and Right Ventricular Mass Measurements Predict Outcome in Children with Pulmonary Arterial Hypertension
39. Clinical utility of the 4S-AF scheme in predicting progression of atrial fibrillation: data from the RACE V study
40. Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction
41. A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers
42. Multimarker Analysis of Serially Measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, Creatinine, and Prognosis in Acute Heart Failure
43. Clinical utility of the 4S-AF scheme in predicting progression of atrial fibrillation:data from the RACE V study
44. A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers
45. Acute heart failure in the young: Clinical characteristics and biomarker profiles
46. Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients
47. MicroRNAs relate to early worsening of renal function in patients with acute heart failure
48. The value of telemonitoring and ICT-guided disease management in heart failure: Results from the IN TOUCH study
49. The Fontan circulation and the liver: A magnetic resonance diffusion-weighted imaging study
50. Six-minute walking distance and decrease in oxygen saturation during the six-minute walk test in pediatric pulmonary arterial hypertension
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.